Equity Profile

BNTX

BioNTech SE

Health CareBiotechnology$25.1B

May5Tue

Post-Earnings Recap

ReportedQ1-2026Pre-Market6:45 AM EDT

BioNTech Misses on EPS, Stock Down 3.88%

Metric	Actual	Expected	Surprise
EPS	$-2.28	$-1.91	+9.45%
Revenue	—	$159M	—

management commentary, guidance changes, and full analysis available with Pro.

BioNTech Misses on EPS, Stock Down 3.88%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-2.28	$-1.91	+9.45%
Revenue	—	$159M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

BioNTech reported a larger-than-expected loss per share, which contributed to a 3.88% decline in its stock price. The company did not provide revenue figures or guidance, leaving investors uncertain about future performance. The stock reaction indicates investor concern over the missed EPS and lack of clarity on revenue expectations.

Company Snapshot

BioNTech SE is a biotechnology company focused on developing and manufacturing immunotherapies for cancer and infectious diseases. As a key player in the healthcare sector, it gained significant attention for its COVID-19 vaccine, and its ongoing research may impact future treatments and vaccine developments.

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability, and a significant loss is expected this quarter.

$-1.91

Revenue

Revenue figures will indicate the company's ability to generate income, especially as it navigates post-pandemic challenges.

$159M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+9.61%

Avg Stock Reaction

-4.09%

Last Quarter Recap

In the last quarter, BioNTech reported a larger-than-expected loss, which disappointed investors and led to a significant drop in stock price. The company did not provide specific guidance, leaving analysts uncertain about future performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting a continued struggle for BioNTech, with losses projected to widen compared to previous quarters. Revenue expectations are modest, reflecting concerns about the company's post-COVID vaccine market position.

Bull Case

If BioNTech can demonstrate strong revenue growth and better-than-expected cost management, it could signal a recovery and renewed investor confidence in its pipeline.

Bear Case

Conversely, if the company reports wider losses and lower revenue, it may indicate deeper issues with its product pipeline and market strategy, leading to further stock declines.

Key Metrics to Watch

EPS

$-1.91

Earnings per share is a critical measure of profitability, and a significant loss is expected this quarter.

Revenue

$159M

Revenue figures will indicate the company's ability to generate income, especially as it navigates post-pandemic challenges.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BioNTech's revenue exceed the consensus estimate of $159M?

Revenue performance is crucial for assessing the company's recovery trajectory and market demand for its products.

How will management address the expected EPS loss of $-1.91?

Understanding the reasons behind the anticipated losses will provide insights into the company's operational efficiency and future strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate BioNTech's potential for revenue recovery due to its ongoing research and development efforts that could yield new products.

Supporting Evidence

Despite recent losses, BioNTech's pipeline includes promising therapies that could drive future growth.

The options market indicates a significant expected move, suggesting that investors are anticipating a more dynamic outcome than the consensus reflects.

Key Risk

If revenue comes in below $159M, it could signal deeper issues in BioNTech's market strategy.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating BioNTech's ability to recover from recent losses and its future revenue potential.

Bull Confirmed If

Revenue exceeding $159M with a narrower EPS loss than expected would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-1.91 and revenue below $159M would reinforce the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5.9%

Historical Avg

±4.7%

Pricing rich

The options market is pricing in a nearly 6% move, suggesting that investors expect significant volatility around the earnings announcement.

Options are pricing ±6.2% while BNTX has averaged ±4.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

39.5%

Calls (42K)P/C Ratio: 1.66Puts (70K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$5.5M

50,000 sh

1 insider

Net

$5.5M

Net selling

Most Active Insiders· 1 open-market trade

Chief Operating OfficerPoetting Sierk
$5.5M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioNTech beats expectations, history suggests a potential stock increase of around 2.5%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to muted reactions as the market assesses management's commentary on future prospects.

Miss

If the company misses expectations, the stock could drop by about 5.4%, indicating ongoing concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or pipeline advancements.
2Management's commentary on cost management strategies and operational efficiency.
3Insights into market demand for BioNTech's existing products.
4Details on partnerships or collaborations that could enhance revenue.
5Any guidance on future earnings or revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability, and a significant loss is expected this quarter.

$-1.91

Revenue

Revenue figures will indicate the company's ability to generate income, especially as it navigates post-pandemic challenges.

$159M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+9.61%

Avg Stock Reaction

-4.09%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If BioNTech can demonstrate strong revenue growth and better-than-expected cost management, it could signal a recovery and renewed investor confidence in its pipeline.

Bear Case

Conversely, if the company reports wider losses and lower revenue, it may indicate deeper issues with its product pipeline and market strategy, leading to further stock declines.

Key Metrics to Watch

EPS

$-1.91

Earnings per share is a critical measure of profitability, and a significant loss is expected this quarter.

Revenue

$159M

Revenue figures will indicate the company's ability to generate income, especially as it navigates post-pandemic challenges.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BioNTech's revenue exceed the consensus estimate of $159M?

Revenue performance is crucial for assessing the company's recovery trajectory and market demand for its products.

How will management address the expected EPS loss of $-1.91?

Understanding the reasons behind the anticipated losses will provide insights into the company's operational efficiency and future strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate BioNTech's potential for revenue recovery due to its ongoing research and development efforts that could yield new products.

Supporting Evidence

Despite recent losses, BioNTech's pipeline includes promising therapies that could drive future growth.

The options market indicates a significant expected move, suggesting that investors are anticipating a more dynamic outcome than the consensus reflects.

Key Risk

If revenue comes in below $159M, it could signal deeper issues in BioNTech's market strategy.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating BioNTech's ability to recover from recent losses and its future revenue potential.

Bull Confirmed If

Revenue exceeding $159M with a narrower EPS loss than expected would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-1.91 and revenue below $159M would reinforce the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5.9%

Historical Avg

±4.7%

Pricing rich

The options market is pricing in a nearly 6% move, suggesting that investors expect significant volatility around the earnings announcement.

Options are pricing ±6.2% while BNTX has averaged ±4.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

39.5%

Calls (42K)P/C Ratio: 1.66Puts (70K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$5.5M

50,000 sh

1 insider

Net

$5.5M

Net selling

Most Active Insiders· 1 open-market trade

Chief Operating OfficerPoetting Sierk
$5.5M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioNTech beats expectations, history suggests a potential stock increase of around 2.5%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to muted reactions as the market assesses management's commentary on future prospects.

Miss

If the company misses expectations, the stock could drop by about 5.4%, indicating ongoing concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or pipeline advancements.
2Management's commentary on cost management strategies and operational efficiency.
3Insights into market demand for BioNTech's existing products.
4Details on partnerships or collaborations that could enhance revenue.
5Any guidance on future earnings or revenue expectations.